FDA Approves Besremi (ropeginterferon alfa-2b-njft) for Treating Polycythemia Vera
On 12 November 2021, the US Food and Drug Administration (FDA) has approved Besremi (ropeginterferon alfa-2b-njft), developed by Pharma Essentia, for the treatment of polycythemia vera, a blood disorder that causes overproduction of red blood cells. Besremi is the first FDA-approved drug for the treatment of polycythemia vera that can be taken by patients regardless of treatment history.
-
Follow
-
0
-
Embed
-
Share
-
Upload
